Heterologous Immune Responses of Serum IgG and Secretory IgA Against the Spike Protein of Endemic Coronaviruses During Severe COVID-19.
COVID-19
SARS-CoV-2
immune imprinting
seasonal coronaviruses
spike protein
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
19
12
2021
accepted:
11
02
2022
entrez:
31
3
2022
pubmed:
1
4
2022
medline:
9
4
2022
Statut:
epublish
Résumé
Defining immune correlates of disease severity is important to better understand the immunopathogenesis in COVID-19. Here we made use of a protein microarray platform to detect IgG- and IgA-reactive antibodies in sera and saliva respectively, and assess cross-reactivity between SARS-CoV-2 and endemic coronaviruses (eCoVs). IgG responses against the full protein of spike, but not the S1 subunit, were significantly higher in convalescent sera of patients with severe disease compared to mild disease and healthy controls. In addition, we detected reactivity of secretory IgA to eCoVs in saliva of patients with severe disease, not present in patients with moderate disease or seropositive healthy controls. These heterologous immune responses are in line with non-protective cross-reactivity, and support a potential role for immune imprinting in the pathogenesis of severe COVID-19.
Identifiants
pubmed: 35355988
doi: 10.3389/fimmu.2022.839367
pmc: PMC8959642
doi:
Substances chimiques
Antibodies, Viral
0
Immunoglobulin A
0
Immunoglobulin A, Secretory
0
Immunoglobulin G
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
839367Informations de copyright
Copyright © 2022 Smit, van Tol, Wal, van Vulpen, la Grouw, van Lelyveld, Limonard, Bossink, Godeke, Shrestha, Reimerink, Eggink, Reusken, Heron and Thijsen.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nat Rev Microbiol. 2007 Jul;5(7):555-63
pubmed: 17558423
Front Genet. 2021 Oct 22;12:773726
pubmed: 34745235
Nat Med. 2021 Jul;27(7):1178-1186
pubmed: 33953384
Nat Med. 2020 Nov;26(11):1691-1693
pubmed: 32929268
Cell Rep. 2020 Jun 2;31(9):107725
pubmed: 32426212
Elife. 2021 Nov 23;10:
pubmed: 34812143
J Clin Invest. 2021 Nov 1;131(21):
pubmed: 34499051
Science. 2020 Oct 2;370(6512):89-94
pubmed: 32753554
Int J Environ Res Public Health. 2017 Aug 31;14(9):
pubmed: 28858222
J Clin Immunol. 2021 Jul;41(5):906-913
pubmed: 33725211
Cell Rep. 2021 Feb 16;34(7):108737
pubmed: 33545052
Cell. 2021 Apr 1;184(7):1858-1864.e10
pubmed: 33631096
Annu Rev Microbiol. 2019 Sep 8;73:529-557
pubmed: 31226023
JAMA Netw Open. 2021 May 3;4(5):e2110344
pubmed: 34009354
BMC Infect Dis. 2021 Aug 21;21(1):855
pubmed: 34418980
Biochem Biophys Res Commun. 2003 Jan 24;300(4):972-9
pubmed: 12559969
Nature. 2020 Aug;584(7821):457-462
pubmed: 32668444
Transl Res. 2022 Feb;240:26-32
pubmed: 34710636
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Nat Immunol. 2021 Jan;22(1):74-85
pubmed: 32999467
Emerg Microbes Infect. 2020 Dec;9(1):1965-1973
pubmed: 32819220
Nat Commun. 2020 Jul 6;11(1):3436
pubmed: 32632160
Cell Host Microbe. 2022 Jan 12;30(1):83-96.e4
pubmed: 34965382
Sci Immunol. 2020 Jun 26;5(48):
pubmed: 32591408
Sci Transl Med. 2021 Jan 20;13(577):
pubmed: 33288662
Nat Commun. 2021 Apr 6;12(1):2055
pubmed: 33824342
Nat Commun. 2021 Jun 18;12(1):3781
pubmed: 34145263
Front Immunol. 2018 Oct 09;9:2312
pubmed: 30356772
J Clin Virol. 2010 Jun;48(2):104-8
pubmed: 20347384
Nature. 2020 Nov;587(7833):270-274
pubmed: 32726801
Cell Rep Med. 2021 Jan 19;2(1):100189
pubmed: 33495758
Emerg Infect Dis. 2020 Jul;26(7):1478-1488
pubmed: 32267220
Euro Surveill. 2019 Nov;24(48):
pubmed: 31796156
Trends Microbiol. 2021 Jul;29(7):648-662
pubmed: 33896688